- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Gufic Biosciences has announced a board meeting. Key outcomes: The company approved its consolidated financial results for the quarter ended June 30, 2025. Revenue from operations stood at Rs 223.72 Cr, with a Net Profit of Rs 13.07 Cr. Earnings Per Share (EPS) for the quarter was Rs 1.30. Additionally, the Board re-appointed M/s. Poddar & Co. as Cost Auditors for FY26 and M/s. Mittal Agarwal & Co. as Statutory Auditors for a second 5-year term, pending shareholder approval.